• All
  • Financials
  • Insiders
Webull provides the latest Atea Pharmaceuticals, Inc. (AVIR) stock and general news. This information may help you make smarter investment decisions.
About AVIR
Atea Pharmaceuticals, Inc., is a clinical-stage biopharmaceutical company. The Company is focused on discovering, developing and commercializing antiviral therapeutics to improve the lives of patients suffering from life-threatening viral infections. It is focused on development of product candidates to treat coronavirus disease (COVID-19), dengue, chronic hepatitis C (HCV), and respiratory syncytial virus (RSV). Its purine nucleotide prodrug platform develops treatments for life threatening diseases caused by single stranded ribonucleic acid (ssRNA) viral infections. Its lead product candidate, AT-527, is an orally administered, antiviral agent for the treatment of patients with COVID-19. It is developing AT-752, an oral, purine nucleoside prodrug product candidate for the treatment of dengue. It is also developing AT-787 for the treatment of chronic HCV infection, including patients with decompensated cirrhosis. It is evaluating AT-889 and other candidates for the treatment of RSV.